Silencing of WNK2 is associated with upregulation of MMP2 and JNK in gliomas

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1422-1434

  Costa, Angela Margarida ^a,b   Pinto, Filipe ^a,b   Martinho, Olga ^a,b   Oliveira, Maria José ^c   Jordan, Peter ^d,e   Reis, Rui Manuel ^a,b,f  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^d NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^e UNIVERSITY OF LISBON   (Portugal)

^f BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Gliomas; Invasion; JNK; MMP2; WNK2

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 6; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNK2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MMP2 PROTEIN, HUMAN; WNK2 PROTEIN, HUMAN;

ARTICLE; CELL INVASION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA METHYLATION; DOWN REGULATION; GLIOMA CELL LINE; HUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WNK2 GENE; BIOSYNTHESIS; BRAIN TUMOR; ENZYMOLOGY; GENE SILENCING; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84922691567     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Louis D.N, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114:97-109.
2. Wen P.Y, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359:492-507.
3. Mareel M, Leroy A. Clinical cellular and molecular aspects of cancer invasion. Physiol Rev. 2003; 83:337-76.
4. Chakraborti S, et al. Regulation of matrix metalloproteinases an overview. Mol Cell Biochem. 2003; 253:269-85.
5. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92:827-39.
6. Parks W.C, Wilson C.L, Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004; 4:617-29.
7. McCawley L.J, Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001; 13:534-40.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2:161-74.
9. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003; 3:489-501.
10. Bellail A.C, et al. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004; 36:1046-69.
11. Verissimo F, Jordan P. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene. 2001; 20:5562-9.
12. Manning G, et al. The protein kinase complement of the human genome. Science. 2002; 298:1912-34.
13. Moniz S, et al. Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. Oncogene. 2007; 26:6071-81.
14. Moniz S, Matos P, Jordan P. WNK2 modulates MEK1 activity through the Rho GTPase pathway. Cell Signal. 2008; 20:1762-8.
15. Hong C, et al. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc Natl Acad Sci U S A. 2007; 104:10974-9.
16. Moniz S, et al. Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum Mol Genet. 2013; 22:84-95.
17. Tao R, et al. Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2011; 6:e19862.
18. Dutruel C, et al. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Oncogene. 2014; 33:3401-10.
19. Jun P, et al. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro Oncol. 2009; 11:414-22.
20. Sawaya R.E, et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis. 1996; 14:35-42.
21. Wang M, et al. The expression of matrix metalloproteinase-2 and-9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2003; 20:65-72.
22. Xiao L.J, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol. 2012; 40:1714-24.
23. Song H, et al. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res. 2009; 69:879-86.
24. Fromigue O, Hamidouche Z, Marie P.J. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem. 2008; 283:30549-56.
25. Huang Q, et al. IL-1beta-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 2014; 13:18.
26. Luo Y, Liang F, Zhang Z.Y. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry. 2009; 48:1838-46.
27. Yoon C.H, et al. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene. 2012; 31:4655-66.
28. Xu K, Shu H.K. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res. 2007; 67:6121-9.
29. Dey N, et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008; 68:1862-71.
30. Forsyth P.A, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999; 79:1828-35.
31. Yeung Y.T, et al. Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol. 2013; 168:591-606.
32. Rolhion C, et al. Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg. 2001; 94:97-101.
33. Li R, et al. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep. 2010; 23:1553-9.
34. Kesanakurti D, et al. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha5beta1 integrin in glioma. Oncogene. 2013; 32:327-40.
35. Song J.S, et al. Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells by a Rac/c-Jun N-terminal kinase-dependent pathway. J Immunol. 1999; 163:802-10.
36. Barros P, Jordan P, Matos P. Rac1 signaling modulates BCL-6-mediated repression of gene transcription. Mol Cell Biol. 2009; 29:4156-66.
37. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 2005; 15:87-96.
38. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 2010; 8:23.
39. Nakada M, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol. 1999; 154:417-28.
40. Nakagawa T, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg. 1994; 81:69-77.
41. Wisniewski P, et al. Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFkappaB-TIMP-2 pathway. Cell Signal. 2010; 22:212-20.
42. Stedt H, et al. Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo. Mol Ther Nucleic Acids. 2012; 1:e19.
43. Lund C.V, et al. Reduced glioma infiltration in Src-deficient mice. J Neurooncol. 2006; 78:19-29.
44. Crespo P, et al. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene. 1996; 13:455-60.
45. Minden A, et al. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell. 1995; 81:1147-57.
46. Zhuge Y, Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell invasion across collagen barrier. J Biol Chem. 2001; 276:16248-56.
47. Tong J.J, et al. RhoA regulates invasion of glioma cells via the c-Jun NH2-terminal kinase pathway under hypoxia. Oncol Lett. 2012; 4:495-500.
48. Axelrod M, et al. Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget. 2013; 4:622-35.
49. Zucker S, Cao J, Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000; 19:6642-50.
50. Ohba S, et al. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol. 2009; 95:307-16.
51. Ishii N, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999; 9:469-79.